Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

5,273 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Disseminated intravascular coagulation induced by pazopanib following combination therapy of nivolumab plus ipilimumab in a patient with metastatic renal cell carcinoma.
Hashimoto M, Nakayama T, Fujimoto S, Inoguchi S, Nishimoto M, Kikuchi T, Adomi S, Banno E, De Velasco MA, Saito Y, Shimizu N, Mori Y, Minami T, Fujita K, Nozawa M, Nose K, Yoshimura K, Uemura H. Hashimoto M, et al. Among authors: nakayama t. Anticancer Drugs. 2022 Jan 1;33(1):e818-e821. doi: 10.1097/CAD.0000000000001230. Anticancer Drugs. 2022. PMID: 34486537
Higher neutrophil-to-lymphocyte ratio after the first cycle of the first-line chemotherapy is associated with poor cancer specific survival of upper urinary tract carcinoma patients.
Hashimoto M, Fujita K, Nakayama T, Fujimoto S, Hamaguchi M, Nishimoto M, Kikuchi T, Adomi S, Banno E, De Velasco MA, Saito Y, Shimizu N, Mori Y, Minami T, Nozawa M, Nose K, Yoshimura K, Uemura H. Hashimoto M, et al. Among authors: nakayama t. Transl Androl Urol. 2021 Jul;10(7):2838-2847. doi: 10.21037/tau-21-185. Transl Androl Urol. 2021. PMID: 34430386 Free PMC article.
Evaluation of prognostic efficacy of liver immune status index in predicting postoperative outcomes in hepatocellular carcinoma patients: A multi-institutional retrospective study.
Imaoka Y, Ohira M, Kobayashi T, Honmyo N, Hamaoka M, Onoe T, Takei D, Oishi K, Abe T, Nakayama T, Akabane M, Sasaki K, Ohdan H; Hiroshima Surgical Study Group of Clinical Oncology (HiSCO). Imaoka Y, et al. Among authors: nakayama t. J Hepatobiliary Pancreat Sci. 2024 Sep 23. doi: 10.1002/jhbp.12070. Online ahead of print. J Hepatobiliary Pancreat Sci. 2024. PMID: 39313837
Preliminary results from ASCENT-J02: a phase 1/2 study of sacituzumab govitecan in Japanese patients with advanced solid tumors.
Naito Y, Nakamura S, Kawaguchi-Sakita N, Ishida T, Nakayama T, Yamamoto Y, Masuda N, Matsumoto K, Kogawa T, Sudo K, Shimomura A, Lai C, Zhang D, Iwahori Y, Gary D, Huynh D, Iwata H. Naito Y, et al. Among authors: nakayama t. Int J Clin Oncol. 2024 Sep 20. doi: 10.1007/s10147-024-02589-x. Online ahead of print. Int J Clin Oncol. 2024. PMID: 39302614
Correction: Trastuzumab deruxtecan for the treatment of patients with HER2-positive breast cancer with brain and/or leptomeningeal metastases: an updated overall survival analysis using data from a multicenter retrospective study (ROSET-BM).
Nakayama T, Niikura N, Yamanaka T, Yamamoto M, Matsuura K, Inoue K, Takahara S, Nomura H, Kita S, Yamaguchi M, Aruga T, Shibata N, Shimomura A, Ozaki Y, Sakai S, Takiguchi D, Takata T, Bastanfard A, Shiosakai K, Tsurutani J. Nakayama T, et al. Breast Cancer. 2024 Sep 20. doi: 10.1007/s12282-024-01632-z. Online ahead of print. Breast Cancer. 2024. PMID: 39302559 No abstract available.
Booster vaccination using bivalent DS-5670a/b is safe and immunogenic against SARS-CoV-2 variants in children aged 5-11 years: a phase 2/3, randomized, active-controlled study.
Suzuki R, Suda M, Ishida K, Furihata K, Ota A, Takahashi K, Sakakibara S, Nakayama T, Takeshita F. Suzuki R, et al. Among authors: nakayama t. Front Immunol. 2024 Sep 2;15:1445459. doi: 10.3389/fimmu.2024.1445459. eCollection 2024. Front Immunol. 2024. PMID: 39286253 Free PMC article. Clinical Trial.
5,273 results